Pigmentary Disorders

Ruxolitinib cream (Jakafi, Incyte) demonstrated positive results in 2 phase 3 studies investigating the topical for treatment of vitiligo in patients 12 years and older

Incyte's Phase 2 study evaluating ruxolitinib cream for vitiligo meets primary endpoint, shows improvement in body and facial repigmentation compared to placebo.

A study published by the American Society of Laser Medicine and Surgery reveals the efficacy of the 755-nm picosecond laser as a treatment for melasma in Asian women with darker skin types.

AVITA Therapeutics has launched a study evaluating their RECELL System as a treatment for stable vitiligo.

New research has shed light on how hyperpigmentation occurs. Experts break down what you need to know in this article.

Newer and emerging modalities are addressing the need for better therapeutic options for vitiligo, but there remains a broader need for dermatologists to understand the existing, useful therapies for this disfiguring, but undertreated autoimmune condition.

Vitiligo affects 3 million people of all skin types per year in the U.S. In this article, Dr. Wheeland summarizes the latest updates on vitiligo, highligting promising treatments to come.

New consensus conclusions are important, because managing acquired macular pigmentation is a new frontier in dermatology. The article defines terminology and notes the primary feature common to macular pigmentation conditions.

Do you know the warning signs of life threatening purpura? Dr. Roderick Hay outlines what you need to know about potentially life-threatening conditions involving purpura.

The latest roundup of new dermatology products includes safe ultrasound treatment in the home, skincare for aging skin, and topical pain relief.